SCHEMBL23529932

SCHEMBL23529932

Cn1cnc2nc(Cl)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRPS1 P60891 1/20 0.41
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
GFER P55789 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
DYRK1A Q13627 1/20 0.33
CDK1 P06493 1/20 0.33
PTGER4 P35408 1/20 0.33
GRM5 P41594 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
YTHDC1 Q96MU7 1/20 0.32
KDM4E B2RXH2 2/20 0.32
DPP4 P27487 1/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29492199 1.00 PRPS1 (0.41) PRPS1NPC1RAB9AGFERSMN1; SMN2
SCHEMBL23346896 0.80 DYRK1A (0.44) DYRK1ACDK1GRM5ALDH1A1MAPT
Hydrochloric Acid SCHEMBL26626454 0.78 DYRK1A (0.42) DYRK1ACDK1GRM5ALDH1A1MAPT
Hydrochloric Acid SCHEMBL31362150 0.78 DYRK1A (0.42) DYRK1ACDK1GRM5ALDH1A1MAPT
SCHEMBL10238677 0.78 PRPS1 (0.42) PRPS1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL13137283 0.76 DYRK1A (0.33) NPC1RAB9ADYRK1AGRM5ALDH1A1
SCHEMBL21733156 0.76 PRPS1 (0.44) PRPS1NPC1RAB9AGFERSMN1; SMN2
SCHEMBL20665100 0.76 HCAR3 (0.40) PRPS1NPC1RAB9AGFERSMN1; SMN2
SCHEMBL26796178 0.73 NPC1 (0.34) NPC1RAB9AGFERSMN1; SMN2TP53
SCHEMBL7869023 0.73 PRPS1 (0.51) PRPS1SMN1; SMN2TP53ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-05-26 US disclosed
EP-4079734-B1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) 2025-09-17 EP disclosed
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 EP disclosed
US-11957683-B2 Bicyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-16 US disclosed
CN-114302886-B Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2024-03-22 CN disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 US disclosed
US-20230382909-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-30 US disclosed
WO-2023205653-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2023-05-04 US disclosed
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2023-05-04 US disclosed
US-20230051483-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-02-16 US disclosed
WO-2022266193-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
EP-4079734-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2022-10-26 EP disclosed
CN-114302886-A Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2022-04-08 CN disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 WO disclosed
WO-2021121294-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海赛默罗生物科技有限公司 2021-06-24 WO disclosed
WO-2021121294-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海赛默罗生物科技有限公司 2021-06-24 WO disclosed
CN-112979655-A Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2021-06-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B PRPS1 1886/4885NPC1 618/4885RAB9A 4615/4885
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 PRPS1 1790/4885NPC1 630/4885RAB9A 4177/4885
US-20230136194-A1 TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF ABCG2, CYP4F8, CYP3A5 PRPS1 733/4885NPC1 1320/4885RAB9A 4055/4885
US-20230051483-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 PRPS1 2950/4885NPC1 11/4885RAB9A 277/4885
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators GABRA6, GABRA1, GABRB1 PRPS1 1366/4885NPC1 357/4885RAB9A 3820/4885
US-20230382909-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 PRPS1 2950/4885NPC1 11/4885RAB9A 277/4885
US-11957683-B2 Bicyclic compounds SLC10A1, PKD1, CYP11B2 PRPS1 2950/4885NPC1 11/4885RAB9A 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.